2019
Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations
Publication
Publication
Clinical Pharmacokinetics , Volume 58 - Issue 6 p. 767- 780
Abstract
Background and Objectives
Uncertainty exists regarding the optimal dosing regimen for vancomycin in diferent patient
populations, leading to a plethora of subgroup-specifc pharmacokinetic models and derived dosing regimens. We aimed to
investigate whether a single model for vancomycin could be developed based on a broad dataset covering the extremes of
patient characteristics. Furthermore, as a benchmark for current dosing recommendations, we evaluated and optimised the
expected vancomycin exposure throughout life and for specifc patient subgroups.
Methods
A pooled population-pharmacokinetic model was built in NONMEM based on data from 14 diferent studies in
diferent patient populations. Steady-state exposure was simulated and compared across patient subgroups for two US Food
and Drug Administration/European Medicines Agency-approved drug labels and optimised doses were derived.
Results
The fnal model uses postmenstrual age, weight and serum creatinine as covariates. A 35-year-old, 70-kg patient
with a serum creatinine level of 0.83 mg dL−1 (73.4 µmol L−1) has a V1, V2, CL and Q2 of 42.9 L, 41.7 L, 4.10 L h−1 and
3.22 L h−1. Clearance matures with age, reaching 50% of the maximal value (5.31 L h−1 70 kg−1) at 46.4 weeks postmenstrual age then declines with age to 50% at 61.6 years. Current dosing guidelines failed to achieve satisfactory steady-state
exposure across patient subgroups. After optimisation, increased doses for the Food and Drug Administration label achieve
consistent target attainment with minimal (±20%) risk of under- and over-dosing across patient subgroups.
Conclusions
A population model was developed that is useful for further development of age and kidney function-stratifed
dosing regimens of vancomycin and for individualisation of treatment through therapeutic drug monitoring and Bayesian
forecasting.
Additional Metadata | |
---|---|
doi.org/10.1007/s40262-018-0727-5, hdl.handle.net/1765/117117 | |
Clinical Pharmacokinetics | |
Organisation | Department of Pediatric Surgery |
Colin, P.J., Allegaert, K., Thomson, A.H., Touw, D., Dolton, M., de Hoog, M., … Eleveld, D.J. (2019). Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations. Clinical Pharmacokinetics, 58(6), 767–780. doi:10.1007/s40262-018-0727-5 |